Abstract

Human immunodeficiency virus (HIV) infection is the determining factor in the development of acquired immunodeficiency syndrome (AIDS). At present there is no effective vaccine against this disease. The objectives of this project are to characterize HIV antigens, determine the targets of humoral and cell mediated immunity, and to use this information to develop candidate vaccines. We have constructed recombinant vaccinia viruses containing genetic information of HIV and the closely related simian immunodeficiency virus. These recombinant viruses have been used to prepare purified immunogens, monoclonal antibodies, targets for cytotoxic T cells and candidate vaccines

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000416-18
Application #
6506830
Study Section
(LVD)
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Cox, Josephine H; Ferrari, Maria G; Earl, Patricia et al. (2012) Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine 30:1830-40
Wyatt, Linda S; Earl, Patricia L; Xiao, Wei et al. (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83:7176-84
Wyatt, Linda S; Belyakov, Igor M; Earl, Patricia L et al. (2008) Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 372:260-72
Wyatt, Linda S; Earl, Patricia L; Vogt, Jennifer et al. (2008) Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26:486-93
Earl, Patricia L; Americo, Jeffrey L; Wyatt, Linda S et al. (2007) Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 366:84-97
Brave, Andreas; Boberg, Andreas; Gudmundsdotter, Lindvi et al. (2007) A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 15:1724-33
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67
Robinson, Harriet L; Sharma, Sunita; Zhao, Jun et al. (2007) Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses 23:1555-62
Liu, Jinyan; Hellerstein, Michael; McDonnel, Michael et al. (2007) Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost. Vaccine 25:2951-8
Kwissa, Marcin; Amara, Rama R; Robinson, Harriet L et al. (2007) Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204:2733-46

Showing the most recent 10 out of 60 publications